Ocular Therapeutix Q4 2023 GAAP EPS $(0.35) Misses $(0.30) Estimate, Sales $14.802M Miss $15.707M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutix reported Q4 2023 GAAP EPS of $(0.35), missing the $(0.30) estimate, with sales of $14.802M also missing the $15.707M estimate. This represents a 5.16% increase in sales compared to the same period last year.
March 11, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ocular Therapeutix reported a Q4 2023 GAAP EPS of $(0.35), missing estimates, and sales of $14.802M, also below expectations but showing a year-over-year growth.
Missing both EPS and sales estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. However, the year-over-year sales growth may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100